webinar register page

Webinar banner
Pharma - Rare Genetic Diseases
Will progress in therapies that promise a genetic cure for devastating rare diseases lead to similar innovations in patient access to these high-cost, high-touch treatments?

Oct 26, 2022 02:00 PM in Eastern Time (US and Canada)

Webinar logo
* Required information
Loading

Speakers

Blueprint Medicines Inc.
Dr. Colin Hislop, M.B.B.S
Senior Vice President, Clinical and Development Operations @Eiger Biopharmaceuticals, Inc.
Dr. Hislop has over 30 years of experience in drug development including small molecules, peptides and biologics, across therapeutic areas in both large pharma and start-up companies. Dr. Hislop began his industry career at Eli Lilly as Medical Director of Endocrinology for insulin and growth hormone. He later led the development of Actonel® through initial FDA approvals for osteoporosis at Proctor & Gamble. He was next Vice President of Clinical Development at CV Therapeutics where he worked on the development and NDA for Ranexa® for angina. He then became Vice President and Head of Clinical Development at Peninsula Pharmaceuticals developing doripenem, a beta-lactam antibiotic for systemic infections, through Phase 2, acquired by J&J. He was later Chief Medical Officer at Anthera and Versartis. During his career, Dr. Hislop has been involved in all phases of drug development from IND to Phase 4,and has led numerous US, European and global regulatory filings, including 4 NDAs.
Merck & Co.
Pam Vig, PhD
Head of R&D @Mirum Pharmaceuticals, Inc.
Pamela Vig, Ph.D. joined Mirum in 2018 as chief scientific officer and was promoted in 2021 to head of R&D where she leads the scientific and clinical aspects of drug development and research, and medical affairs. Pam has more than 25 years of industry experience in clinical development, medical affairs and translational science in various liver diseases including hepatitis B (HBV), hepatitis C (HCV), nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and cholestatic liver disease, as well as HIV and other infectious diseases. Before joining Mirum, Pam held leadership roles at Allergan plc and Tobira Therapeutics as vice president of clinical research and discovery, as well as vice president of clinical research at Presidio Pharmaceuticals, Inc.
Merck & Co.